2025 Q4 -tulosraportti
Vain PDF
9 päivää sitten
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 817 | - | - | ||
| 6 356 | - | - | ||
| 3 139 | - | - | ||
| 4 171 | - | - | ||
| 829 | - | - |
Ylin
1,15VWAP
Alin
1,015VaihtoMäärä
0,1 110 352
VWAP
Ylin
1,15Alin
1,015VaihtoMäärä
0,1 110 352
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 23.7. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 7.11.2025 | ||
2025 Q2 -tulosraportti 23.7.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 | ||
2024 Q2 -tulosraportti 26.7.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sittenI am not going to advertise or recommend. But for those who are interested in prostate cancer, I just want to say that I came across this stock today. I would have liked to have heard about it before. It is in no way a competitor or makes Prostatype unnecessary.
·2 päivää sittenwe need to get up towards 2 and with bigger news, the rocket is unstoppable 🚀 the management fights tooth and nail for its shareholders 🥰 they know the goal is near and there are many years of hard work behind it 💪 so they don't give up 🥰
·2 päivää sittenI have never encountered anyone who so often comments on a single stock, and doesn't own any themselves? Or do you have them on another platform or just an interest in the company?
·2 päivää sittenThen people realized that everything below price 1 was cheap...·2 päivää sittenAs "Baldersen" also wrote on Feb 28... Prostatype's study in the USA was recently presented in a scientific journal, where the statistical calculations were interpreted as predominantly positive, and it is believed that the publication of the study can accelerate a decision from the company reviewing the application for Medicare. If a positive result is achieved, we estimate that a market worth 350-400 million USD will open up for Prostatype, but competition from established tests will be tough. As stated in the news on the left side... In my view, it would be unrealistic for the share price, which immediately has no resistance before the last peak at 1.9+, to be held here below / just around price 1, but it will return to the 1.3 level within the next couple of months, without new news. My guess...- ·26.2. · MuokattuI have corrected typos in previous posts, which have now been deleted. Hereafter it looks like this: One could write that a liquidity need arises. Perhaps in May, as Baldersen writes. That's no secret. But it can be covered in other ways than an issue! E.g., through loans or via an agreement with a partner. And an issue can be both a directed issue, which I would then prefer, rather than a rights issue, which often ends incredibly badly. Unfortunately, most people think of the latter when one just writes "issue", because one has experienced so dreadfully many failed rights issues.
·28.2. · MuokattuThe matter is, in short, that they must get a positive answer from Medicare by around May (give or take a bit, hard to be completely sure), so they can start real sales in the USA. That should make the share price rise significantly and a share issue can be carried out at a higher price, and thereby the dilution will be minimal and the potential will be great (whether they subsequently deliver on that is another matter, but it will be a new and promising case with reimbursement). If they don't get an answer by then, it doesn't look so good for the existing shareholders. Their current liabilities are high, and in that is probably included the repayment of the loan ("The loans carry a fixed interest rate of about 15 percent and shall be repaid, including accrued interest, no later than 30 June 2026."). As Benielsen writes, there is naturally a possibility that the loan can be extended or other loans can be taken out. And a directed issue is also a possibility. That will either give them additional time to get an answer from Medicare or at least ensure that the existing shareholders are better off than worst-case. The loan in January was surprisingly positive and we initially avoided a share issue, so it is possible that they find other ways. So, it's very high risk. Good opportunity for some (or if there's hype in the stock, then maybe many) hundreds of percent in return in under 3 months or to lose almost everything.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
9 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenI am not going to advertise or recommend. But for those who are interested in prostate cancer, I just want to say that I came across this stock today. I would have liked to have heard about it before. It is in no way a competitor or makes Prostatype unnecessary.
- ·2 päivää sittenwe need to get up towards 2 and with bigger news, the rocket is unstoppable 🚀 the management fights tooth and nail for its shareholders 🥰 they know the goal is near and there are many years of hard work behind it 💪 so they don't give up 🥰·2 päivää sittenI have never encountered anyone who so often comments on a single stock, and doesn't own any themselves? Or do you have them on another platform or just an interest in the company?
- ·2 päivää sittenThen people realized that everything below price 1 was cheap...·2 päivää sittenAs "Baldersen" also wrote on Feb 28... Prostatype's study in the USA was recently presented in a scientific journal, where the statistical calculations were interpreted as predominantly positive, and it is believed that the publication of the study can accelerate a decision from the company reviewing the application for Medicare. If a positive result is achieved, we estimate that a market worth 350-400 million USD will open up for Prostatype, but competition from established tests will be tough. As stated in the news on the left side... In my view, it would be unrealistic for the share price, which immediately has no resistance before the last peak at 1.9+, to be held here below / just around price 1, but it will return to the 1.3 level within the next couple of months, without new news. My guess...
- ·26.2. · MuokattuI have corrected typos in previous posts, which have now been deleted. Hereafter it looks like this: One could write that a liquidity need arises. Perhaps in May, as Baldersen writes. That's no secret. But it can be covered in other ways than an issue! E.g., through loans or via an agreement with a partner. And an issue can be both a directed issue, which I would then prefer, rather than a rights issue, which often ends incredibly badly. Unfortunately, most people think of the latter when one just writes "issue", because one has experienced so dreadfully many failed rights issues.·28.2. · MuokattuThe matter is, in short, that they must get a positive answer from Medicare by around May (give or take a bit, hard to be completely sure), so they can start real sales in the USA. That should make the share price rise significantly and a share issue can be carried out at a higher price, and thereby the dilution will be minimal and the potential will be great (whether they subsequently deliver on that is another matter, but it will be a new and promising case with reimbursement). If they don't get an answer by then, it doesn't look so good for the existing shareholders. Their current liabilities are high, and in that is probably included the repayment of the loan ("The loans carry a fixed interest rate of about 15 percent and shall be repaid, including accrued interest, no later than 30 June 2026."). As Benielsen writes, there is naturally a possibility that the loan can be extended or other loans can be taken out. And a directed issue is also a possibility. That will either give them additional time to get an answer from Medicare or at least ensure that the existing shareholders are better off than worst-case. The loan in January was surprisingly positive and we initially avoided a share issue, so it is possible that they find other ways. So, it's very high risk. Good opportunity for some (or if there's hype in the stock, then maybe many) hundreds of percent in return in under 3 months or to lose almost everything.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 817 | - | - | ||
| 6 356 | - | - | ||
| 3 139 | - | - | ||
| 4 171 | - | - | ||
| 829 | - | - |
Ylin
1,15VWAP
Alin
1,015VaihtoMäärä
0,1 110 352
VWAP
Ylin
1,15Alin
1,015VaihtoMäärä
0,1 110 352
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 23.7. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 7.11.2025 | ||
2025 Q2 -tulosraportti 23.7.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 | ||
2024 Q2 -tulosraportti 26.7.2024 |
2025 Q4 -tulosraportti
Vain PDF
9 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 23.7. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 7.11.2025 | ||
2025 Q2 -tulosraportti 23.7.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 | ||
2024 Q2 -tulosraportti 26.7.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenI am not going to advertise or recommend. But for those who are interested in prostate cancer, I just want to say that I came across this stock today. I would have liked to have heard about it before. It is in no way a competitor or makes Prostatype unnecessary.
- ·2 päivää sittenwe need to get up towards 2 and with bigger news, the rocket is unstoppable 🚀 the management fights tooth and nail for its shareholders 🥰 they know the goal is near and there are many years of hard work behind it 💪 so they don't give up 🥰·2 päivää sittenI have never encountered anyone who so often comments on a single stock, and doesn't own any themselves? Or do you have them on another platform or just an interest in the company?
- ·2 päivää sittenThen people realized that everything below price 1 was cheap...·2 päivää sittenAs "Baldersen" also wrote on Feb 28... Prostatype's study in the USA was recently presented in a scientific journal, where the statistical calculations were interpreted as predominantly positive, and it is believed that the publication of the study can accelerate a decision from the company reviewing the application for Medicare. If a positive result is achieved, we estimate that a market worth 350-400 million USD will open up for Prostatype, but competition from established tests will be tough. As stated in the news on the left side... In my view, it would be unrealistic for the share price, which immediately has no resistance before the last peak at 1.9+, to be held here below / just around price 1, but it will return to the 1.3 level within the next couple of months, without new news. My guess...
- ·26.2. · MuokattuI have corrected typos in previous posts, which have now been deleted. Hereafter it looks like this: One could write that a liquidity need arises. Perhaps in May, as Baldersen writes. That's no secret. But it can be covered in other ways than an issue! E.g., through loans or via an agreement with a partner. And an issue can be both a directed issue, which I would then prefer, rather than a rights issue, which often ends incredibly badly. Unfortunately, most people think of the latter when one just writes "issue", because one has experienced so dreadfully many failed rights issues.·28.2. · MuokattuThe matter is, in short, that they must get a positive answer from Medicare by around May (give or take a bit, hard to be completely sure), so they can start real sales in the USA. That should make the share price rise significantly and a share issue can be carried out at a higher price, and thereby the dilution will be minimal and the potential will be great (whether they subsequently deliver on that is another matter, but it will be a new and promising case with reimbursement). If they don't get an answer by then, it doesn't look so good for the existing shareholders. Their current liabilities are high, and in that is probably included the repayment of the loan ("The loans carry a fixed interest rate of about 15 percent and shall be repaid, including accrued interest, no later than 30 June 2026."). As Benielsen writes, there is naturally a possibility that the loan can be extended or other loans can be taken out. And a directed issue is also a possibility. That will either give them additional time to get an answer from Medicare or at least ensure that the existing shareholders are better off than worst-case. The loan in January was surprisingly positive and we initially avoided a share issue, so it is possible that they find other ways. So, it's very high risk. Good opportunity for some (or if there's hype in the stock, then maybe many) hundreds of percent in return in under 3 months or to lose almost everything.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 817 | - | - | ||
| 6 356 | - | - | ||
| 3 139 | - | - | ||
| 4 171 | - | - | ||
| 829 | - | - |
Ylin
1,15VWAP
Alin
1,015VaihtoMäärä
0,1 110 352
VWAP
Ylin
1,15Alin
1,015VaihtoMäärä
0,1 110 352
Välittäjätilasto
Dataa ei löytynyt